100
Participants
Start Date
December 31, 2011
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
AXL1717
AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Docetaxel
Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
Semmelweis University; Clinic for Pulmonology, Budapest
University of Debrecen Medical and Health Science Center, Clinic of Pulmonology, Debrecen
Kenezy Gyula County Hospital, Debrecen
Hospital for Thoracic Diseases of Csongrad County Local Government, Deszk
Dnipropetrovsk City Multispecialty Clinical Hospital #4, Dniepropetrovsk
Kharkiv, State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Kharkiv
Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center, Kharkiv
Lviv State Regional Treatment and Diagnostics Oncology Center, Lviv
Public Clinical Treatment and Prophylaxis Institution: Donetsk Regional Antitumor Center, Donetsk
Zakarpattia Regional Clinical Oncology Center, Uzhhorod
St. Petersburg State Medical Institution Municipal Clinical Oncology Center, Saint Petersburg
State Higher Educational Institution St. Petersburg State Medical University n. a. after I. P. Pavlov under Federal Agency for Healthcare and Social Development, Research Institute of Pulmonology, Saint Petersburg
Vitebsk Regional Clinical Oncology Center, Vitebsk
Minsk City Clinical Oncology Center, Minsk
State Medical Institution: Republic Scientific Oncology Center, Poselok
Gomel Regional Clinical Oncology Center, Homyel
Tula Regional Oncology Center, Tula
Orel Oncology Center, Oryol
State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncology Center, Chelyabinsk
Sverdlovsk Regional Oncology Center, Yekaterinburg
City Clinical Hospital #1, Novosibirsk
Wladyslaw Bieganski Regional Specialist Hospital, Grudziądz
Maria Sklodowska-Curie Institute of Oncology in Warsaw, Warsaw
Kyiv City Oncology Hospital, Kyiv
Lead Sponsor
Axelar AB
INDUSTRY